18807-71-1

Basic information

• Product Name: BENZYL N-(2-AMINOETHYL)CARBAMATE HYDROCHLORIDE
• Synonyms: BENZYL N-(2-AMINOETHYL)CARBAMATE HYDROCHLORIDE;TIMTEC-BB SBB003280;N-CBZ-1,2-DIAMINOETHANE HYDROCHLORIDE;N-Z-ETHYLENEDIAMINE HYDROCHLORIDE;N-Z-1,2-DIAMINOETHANE HYDROCHLORIDE;N-BENZYLOXYCARBONYL-1,2-DIAMINOETHANE HYDROCHLORIDE;N-CARBOBENZOXY-1,2-DIAMINOETHANE HYDROCHLORIDE;N-1-Z-1,2-DIAMINOETHANE HCL
• CAS NO: 18807-71-1
• Molecular Formula: C₁₀H₁₄N₂O₂*ClH
• Molecular Weight: 230.69
• Product Categories: N-Cbz-diaminoalkanes;Monoprotected Diaminoalkanes;Protected Amines;Bifunctional Crosslinkers;Building Blocks;Chemical Biology;Chemical Synthesis;Linkers;Nitrogen Compounds;Organic Building Blocks;Peptide Chemistry
• Mol File: 18807-71-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 169-172 °C(lit.)
• Boiling Point: 383.2°C at 760 mmHg
• Flash Point: 185.6°C
• Appearance: Slightly yellow to brown/Solution Product May Develop Some Turbidity or Precipitate
• Vapor Pressure: 3E-06mmHg at 25°C
• Storage Temp.: Store at 0-5°C
• Water Solubility: Soluble in water
• BRN: 4724532
• CAS DataBase Reference: BENZYL N-(2-AMINOETHYL)CARBAMATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL N-(2-AMINOETHYL)CARBAMATE HYDROCHLORIDE(18807-71-1)
• EPA Substance Registry System: BENZYL N-(2-AMINOETHYL)CARBAMATE HYDROCHLORIDE(18807-71-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• F: 3
• Hazardous Substances Data: 18807-71-1(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

InChI:InChI=1/C10H14N2O2.ClH/c11-6-7-12-10(13)14-8-9-4-2-1-3-5-9;/h1-5H,6-8,11H2,(H,12,13);1H

Upstream product

• 72080-83-2 2-benzyloxycarbonylaminoethylamine 
• 146552-66-1 benzyl (2-azidoethyl)carbamate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 107-15-3 ethylenediamine 
• 501-53-1 benzyl chloroformate 
• 61495-86-1 N,N-Bis-Carbobenzyloxyethylenediamine 
• 18807-67-5 1,2-Ethanediylbis(phenylmethyl carbamate) 
• 77153-05-0 N¹-benzyloxycarbonyl-N²-t-butoxycarbonyl-1,2-ethanediamine 
• 886-64-6 N^β-benzyloxycarbonyl-β-alaninamide 

Downstream Products

• 850033-18-0 (+/-)-2-[2-[(benzyloxycarbonyl)amino]ethyl]-1-carbonitrile-1,3-dihydro-4-trifluoromethoxyisoindol-3(1H)-one 
• 223742-32-3 1-N-chloroacetyl-2-N'-Cbz(ethylenediamine) 
• 82825-43-2 Boc-Asp(OBzl)EDA-Z 
• 848083-53-4 C₂₈H₃₉N₅O₆ 
• 1429324-50-4 C₂₇H₂₉N₅O₅ 
• 1429324-49-1 C₂₁H₂₄BrN₅O₄ 
• 1313712-89-8 4-(aminoethylcarbamoyl)-3-fluorophenylboronic acid 

Relevant articles and documents

NOVEL ANTIBACTERIAL 3"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS

The present invention relates to novel aminoglycoside compounds having antimicrobial properties and being suitable, for example, as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The invention further relates to compounds for use in the treatment of diseases whose treatment is made otherwise difficult due to antibiotic-class-related bacterial resistance and provides novel therapeutic agents suitable for use in the treatment of multidrug-resistant (MDR) infections.

MIC-1 Compounds and Uses Thereof

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

FGF21 DERIVATIVES AND USES THEREOF

The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.